These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

648 related items for PubMed ID: 16332942

  • 21. Drug utilisation and cost considerations of erythropoiesis stimulating agents in oncology patients receiving chemotherapy: observations from a large managed-care database.
    Vekeman F, McKenzie RS, Bookhart BK, Laliberté F, Duh MS, Tak Piech C, Lefebvre P.
    J Med Econ; 2009 Mar; 12(1):1-8. PubMed ID: 19450059
    [Abstract] [Full Text] [Related]

  • 22. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients.
    Nissenson AR, Swan SK, Lindberg JS, Soroka SD, Beatey R, Wang C, Picarello N, McDermott-Vitak A, Maroni BJ.
    Am J Kidney Dis; 2002 Jul; 40(1):110-8. PubMed ID: 12087568
    [Abstract] [Full Text] [Related]

  • 23. Use of darbepoetin alfa and epoetin alfa in clinical practice in patients with cancer-related anemia.
    Berger A, Edelsberg J, Kallich J, Oster G.
    Clin Ther; 2008 Jan; 30(1):206-18. PubMed ID: 18343258
    [Abstract] [Full Text] [Related]

  • 24. Darbepoetin alfa: potential role in managing anemia in cancer patients.
    Pirker R, Smith R.
    Expert Rev Anticancer Ther; 2002 Aug; 2(4):377-84. PubMed ID: 12647980
    [Abstract] [Full Text] [Related]

  • 25. Australian haemodialysis patients on intravenous epoetin alfa or intravenous darbepoetin alfa: how do they compare?
    Pussell BA, Walker R, Australian Renal Anaemia Group.
    Nephrology (Carlton); 2007 Apr; 12(2):126-9. PubMed ID: 17371333
    [Abstract] [Full Text] [Related]

  • 26. Every 3 weeks dosing with darbepoetin alfa: A new paradigm in anaemia management.
    Vansteenkiste JF.
    Cancer Treat Rev; 2006 Apr; 32 Suppl 2():S11-5. PubMed ID: 16725268
    [Abstract] [Full Text] [Related]

  • 27. Guidelines and recommendations for the management of anaemia in patients with lymphoid malignancies.
    Henry DH.
    Drugs; 2007 Apr; 67(2):175-94. PubMed ID: 17284083
    [Abstract] [Full Text] [Related]

  • 28. A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment.
    Wilson J, Yao GL, Raftery J, Bohlius J, Brunskill S, Sandercock J, Bayliss S, Moss P, Stanworth S, Hyde C.
    Health Technol Assess; 2007 Apr; 11(13):1-202, iii-iv. PubMed ID: 17408534
    [Abstract] [Full Text] [Related]

  • 29. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
    Voravud N, Sriuranpong V.
    J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
    [Abstract] [Full Text] [Related]

  • 30. Epoetin alfa and darbepoetin alfa go head to head.
    Steensma DP, Loprinzi CL.
    J Clin Oncol; 2006 May 20; 24(15):2233-6. PubMed ID: 16710021
    [No Abstract] [Full Text] [Related]

  • 31. Tale of Two Erythropoiesis-Stimulating Agents: Utilization, Dosing, Litigation, and Costs of Darbepoetin and Epoetin Among South Carolina Medicaid-Covered Patients With Cancer and Chemotherapy-Induced Anemia.
    Noxon V, Knopf KB, Norris LB, Chen B, Yang YT, Qureshi ZP, Hrushesky W, Lebby AA, Schooley B, Hikmet N, Dickson M, Thamer M, Cotter D, Yarnold PR, Bennett CL.
    J Oncol Pract; 2017 Jun 20; 13(6):e562-e573. PubMed ID: 28504901
    [Abstract] [Full Text] [Related]

  • 32. What is the practical conversion dose when changing from epoetin alfa to darbepoetin outside of clinical trials?
    Roger SD, Cooper B.
    Nephrology (Carlton); 2004 Aug 20; 9(4):223-8. PubMed ID: 15363054
    [Abstract] [Full Text] [Related]

  • 33. Epoetin alfa and darbepoetin alfa for the treatment of chemotherapy-related anemia in cancer patients in Sweden: comparative analysis of drug utilization, costs, and hematologic response.
    Persson U, Borg S, Jansson S, Ekman T, Franksson L, Friesland S, Larsson AM.
    Adv Ther; 2005 Aug 20; 22(3):208-24. PubMed ID: 16236682
    [Abstract] [Full Text] [Related]

  • 34. Utilization of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia.
    Herrington JD, Davidson SL, Tomita DK, Green L, Smith RE, Boccia RV.
    Am J Health Syst Pharm; 2005 Jan 01; 62(1):54-62. PubMed ID: 15658073
    [Abstract] [Full Text] [Related]

  • 35. Darbepoetin alfa administered every 2 weeks alleviates anemia in cancer patients receiving chemotherapy.
    Glaspy JA, Tchekmedyian NS.
    Oncology (Williston Park); 2002 Oct 01; 16(10 Suppl 11):23-9. PubMed ID: 12435170
    [Abstract] [Full Text] [Related]

  • 36. Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly.
    Senecal FM, Yee L, Gabrail N, Charu V, Tomita D, Rossi G, Schwartzberg L.
    Clin Breast Cancer; 2005 Dec 01; 6(5):446-54. PubMed ID: 16381629
    [Abstract] [Full Text] [Related]

  • 37. A retrospective cohort study to assess the impact of therapeutic substitution of darbepoetin alfa for epoetin alfa in anemic patients with myelodysplastic syndrome.
    Patton JF, Sullivan T, Mun Y, Reeves T, Rossi G, Wallace JF.
    J Support Oncol; 2005 Dec 01; 3(6):419-26. PubMed ID: 16350429
    [Abstract] [Full Text] [Related]

  • 38. Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature.
    Ross SD, Allen IE, Henry DH, Seaman C, Sercus B, Goodnough LT.
    Clin Ther; 2006 Jun 01; 28(6):801-31. PubMed ID: 16860166
    [Abstract] [Full Text] [Related]

  • 39. Propensity score matched assessment of treatment patterns and cost of erythropoiesis stimulating agent treatment in patients with cancer receiving myelosuppressive chemotherapy.
    Tunceli O, Bailey RA, Stephenson JJ, Singer J.
    J Oncol Pharm Pract; 2013 Dec 01; 19(4):305-14. PubMed ID: 23235918
    [Abstract] [Full Text] [Related]

  • 40. Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia.
    Boccia R, Malik IA, Raja V, Kahanic S, Liu R, Lillie T, Tomita D, Clowney B, Silberstein P.
    Oncologist; 2006 Apr 01; 11(4):409-17. PubMed ID: 16614237
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 33.